Foot and ankle surgeons at NYU Langone Health and Baptist Health South Florida reviewed BPC-157, thymosin beta-4, and TB-500 in the Journal of the American Academy of Orthopaedic Surgeons on October 27, 2026. BPC-157 has the most animal data for tendon, ligament, muscle, and bone, but human musculoskeletal evidence is one small retrospective case series with no control group; thymosin beta-4's musculoskeletal data come only from lab and rodent studies, and TB-500, a seven-amino-acid fragment, is often confused with the full protein. None has an FDA-approved musculoskeletal use, and the authors advise against routine use and urge surgeons to ask about peptide use and warn athletes about anti-doping rules.
AJSM published a comprehensive review of injectable peptide therapy for orthopedic and sports medicine, surveying BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conclude that while preclinical evidence supports tendon and muscle repair benefits, human trials are minimal — the most-cited BPC-157 human data is a single 12-patient case series with significant methodological flaws. TB-500 and BPC-157 remain WADA-banned. The piece directly addresses surgeons being asked about peptides by patients in the wake of FDA Category 2 changes.
The American Orthopaedic Society for Sports Medicine published an April 2026 update revisiting the evidence base for peptide therapy in sports medicine. The piece reflects increasing surgeon-side concerns about patients self-administering peptides for recovery from injuries and surgeries, with growing pressure from clinics offering BPC-157 and TB-500 injections. AOSSM's stance remains that current evidence is insufficient to recommend therapeutic peptide use — but the educational push acknowledges the rising clinical reality post-FDA reclassification.